Tata Memorial Centre asserts that its Rs 100 per tablet medication has the potential to prevent cancer recurrence. The tablet, developed by the institute, aims to not only prevent cancer from returning but also reduce treatment side effects by half. Currently awaiting approval from FSSAI, once sanctioned, the tablet is anticipated to be available in the market by June.
Trending
- Shreeji Shipping Global Ltd Files for IPO to Fund Expansion and Debt Repayment
- Dalal Street Outlook: Key Developments for the Week Ahead
- Foreign Investors (FPI’s) Withdraw ₹64,156 Crore from Indian Equity Markets in January
- SEBI Imposes ₹12 Lakh Fine on NSE Data and Analytics for Regulatory Violations
- BookMyShow CEO Ashish Hemrajani Skips Second EOW Summons Over Coldplay Concert Ticket Scandal
- TCS to Announce Q2 Results and Consider Interim Dividend on October 10
- Tata Power Signs MoU with Rajasthan Government to Invest ₹1.2 Trillion in Renewable Energy, Transmission, and EV Projects
- SEBI Raises Concerns Over IPO Proceeds Used for Promoter Loan Repayments, Delays Multiple Listings
- IDFC Announces Board Approval for Subsidiary Amalgamation with IDFC FIRST Bank, Effective October 2024
- Jet Airways Lenders Inform Supreme Court of JKC’s Failure to Meet Ownership Transfer Conditions, Risking Liquidation
Ensuring Authenticity, Upholding Trust
